<DOC>
	<DOC>NCT00135369</DOC>
	<brief_summary>The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels &lt;50 copies/mL after switching to a QD regimen.</brief_summary>
	<brief_title>Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented HIV infection 18 years of age or older and weigh at least 40 kg Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit) Currently receiving a standardofcare HAART regimen with at least one agent being dosed twicedaily or more frequently Pregnancy, breastfeeding or plans to become pregnant during the study period Any prior documented virologic failure to one or more HAART regimens Active AIDSdefining opportunistic infection or disease Proven or suspected acute hepatitis within 30 days prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV-AIDS</keyword>
</DOC>